KR890014735A - 변형 단백질 - Google Patents

변형 단백질 Download PDF

Info

Publication number
KR890014735A
KR890014735A KR1019890002759A KR890002759A KR890014735A KR 890014735 A KR890014735 A KR 890014735A KR 1019890002759 A KR1019890002759 A KR 1019890002759A KR 890002759 A KR890002759 A KR 890002759A KR 890014735 A KR890014735 A KR 890014735A
Authority
KR
South Korea
Prior art keywords
compound
formula
thr
asp
tyr
Prior art date
Application number
KR1019890002759A
Other languages
English (en)
Other versions
KR0134377B1 (ko
Inventor
게르아르트 그뤼터 마르쿠스
하인츠 디르크
리르슈 만프레드
Original Assignee
베르너 발데그
시바-가이기 에이지
베르너 에이.레슈타이너
유씨피 겐-파르마 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르너 발데그, 시바-가이기 에이지, 베르너 에이.레슈타이너, 유씨피 겐-파르마 에이지 filed Critical 베르너 발데그
Publication of KR890014735A publication Critical patent/KR890014735A/ko
Application granted granted Critical
Publication of KR0134377B1 publication Critical patent/KR0134377B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8286—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for insect resistance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Pest Control & Pesticides (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)

Abstract

내용 없음.

Description

변형 단백질
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기 일반식(I)의 화합물 및 이의 염
    상기식에서, R은 수소 또는 아세틸이고, W는 Tyr또는 His이고, X는 Thr, Ser 또는 Pre이고, Y는 Leu, Met, Arg, Lys, Phe, Tyr 또는 Trp이며, 2는 Asp, Glu, Gln, Asn, Ala, Ser 또는 Thr이고, 단, Y가 Leu이고 Z가 AsP일 경우, X는 Thr이 아닌 다른 것이다.
  2. 제 1항에 있어서, R은 아세틸이고, W가 Tyr이며, X는 Thr, Y는 Arg 또는 Lys 및 Z는 Asp, Glu, Gln, Asn, Ala, Ser 또는 Thr이거나, X는 Pro, Y는 Met, 및 Z는 Asp이거나, X는 Thr, Y는 Phe, Tyr, Trp 또는 Met, 및 Z는 Asp인 일반식(I)과 화합물 및 이의 염.
  3. 제 1항에 있어서, R은 아세틸이고, W는 Tyr이고, X는 Thr이고, Y는 Arg이며, Z가 AsP 또는 Ser인 일반식(I)의 화합물 및 이의 염.
  4. 제 1항에 따른 Nα-아세틸-[Arg 45]-에그린 C.
  5. 제 1항에 따른 일반식(I)의 화합물 또는 이의 약제학적으로 허용되는 염을 함유하는 약제학적 조성물.
  6. 프로테아제의 억제를 필요로 하는 포유동물에게 치료 유효량의 제 1항에 따른 일반식(I)의 화합물 또는 이의 약제학적으로 허용되는 염을 투여함을 특징으로 하여, 상기 포유동물의 체내의 엘라스타제, 트롬빈 및 트립신으로 이루어진 그룹중에서 선택된 프로테아제를 억제하는 방법.
  7. 일반식(I)의 화합물을 암호화하는 DNA를 함유한 형질전환된 숙주 미생물을 배양하고, 이로부터 이반식(I)의 화합물 또는 이의 염을 분리시킴을 특징으로 하여, 제 1항에 다른 일반식(I)의 화합물 및 이의 염을 제조하는 방법.
  8. 제 1항에 따른 일반식(I)의 화합물을 암호화하는 DNA 서열을 함유하는 DNA.
  9. 제 1항에 따른 일반식(I)의 화합물을 암호화하며 발현 조절 서열에 의해 조절되는 DNA 서열을 함유하는 발현 벡터.
  10. 제 9항에 따른 발현 벡터를 함유하는 숙주 미생물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890002759A 1988-03-07 1989-03-07 에글린 b 및 에글린 c의 돌연변이체, 이를 암호화하는 dna 서열, 이러한 dna를 포함하는 재조합 벡터, 이러한 벡터로 형질전환된 숙주, 돌연변이체를 제조하는 방법 및 돌연변이체를 함유하는 약제학적 조성물 KR0134377B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH840/88-6 1988-03-07
CH84088 1988-03-07

Publications (2)

Publication Number Publication Date
KR890014735A true KR890014735A (ko) 1989-10-25
KR0134377B1 KR0134377B1 (ko) 1998-04-20

Family

ID=4196431

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890002759A KR0134377B1 (ko) 1988-03-07 1989-03-07 에글린 b 및 에글린 c의 돌연변이체, 이를 암호화하는 dna 서열, 이러한 dna를 포함하는 재조합 벡터, 이러한 벡터로 형질전환된 숙주, 돌연변이체를 제조하는 방법 및 돌연변이체를 함유하는 약제학적 조성물

Country Status (20)

Country Link
US (1) US5079229A (ko)
EP (1) EP0332576B1 (ko)
JP (1) JP2716191B2 (ko)
KR (1) KR0134377B1 (ko)
AT (1) ATE103930T1 (ko)
AU (1) AU623881B2 (ko)
CA (1) CA1339105C (ko)
DD (1) DD283645A5 (ko)
DE (1) DE58907373D1 (ko)
DK (1) DK107389A (ko)
ES (1) ES2063161T3 (ko)
FI (1) FI96116C (ko)
HU (1) HU209401B (ko)
IE (1) IE62993B1 (ko)
IL (1) IL89496A0 (ko)
NO (1) NO178870C (ko)
NZ (1) NZ228208A (ko)
PT (1) PT89916B (ko)
TW (1) TW211522B (ko)
ZA (1) ZA891679B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
US5674833A (en) * 1990-09-18 1997-10-07 Novo Nordisk A/S Detergent compositions containing protease and novel inhibitors for use therein
US5604201A (en) * 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
TW492975B (en) * 1993-07-26 2002-07-01 Novartis Ag Tryptase inhibitor
EP0929577B1 (en) 1996-09-24 2003-06-04 The Procter & Gamble Company Stabilized proteinaceous protease inhibitors and variants thereof
US7001884B2 (en) * 2001-06-18 2006-02-21 Regents Of The University Of Michigan Eglin c based drugs for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125047B (en) * 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
DE3324534A1 (de) * 1983-07-07 1985-01-17 Ciba-Geigy Ag, Basel Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel
CA1297437C (en) * 1983-11-21 1992-03-17 Hans Rink Process for the preparation of protease inhibitors
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
EP0164719B1 (en) * 1984-06-14 1992-05-06 Chiron Corporation Active site modified protease alpha-1-antitrypsin inhibitors and their production
HU204563B (en) * 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
GB2199582A (en) * 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor

Also Published As

Publication number Publication date
DE58907373D1 (de) 1994-05-11
TW211522B (ko) 1993-08-21
HUT50503A (en) 1990-02-28
EP0332576B1 (de) 1994-04-06
NO890932L (no) 1989-09-08
DK107389D0 (da) 1989-03-06
KR0134377B1 (ko) 1998-04-20
AU623881B2 (en) 1992-05-28
ATE103930T1 (de) 1994-04-15
FI891020A (fi) 1989-09-08
EP0332576A2 (de) 1989-09-13
NZ228208A (en) 1990-08-28
ES2063161T3 (es) 1995-01-01
FI96116B (fi) 1996-01-31
AU3095989A (en) 1989-09-07
NO178870C (no) 1996-06-19
EP0332576A3 (en) 1990-09-12
NO178870B (no) 1996-03-11
NO890932D0 (no) 1989-03-06
JPH029392A (ja) 1990-01-12
PT89916A (pt) 1989-11-10
DK107389A (da) 1989-09-08
IE890719L (en) 1989-09-07
CA1339105C (en) 1997-07-29
FI891020A0 (fi) 1989-03-03
IL89496A0 (en) 1989-09-10
DD283645A5 (de) 1990-10-17
ZA891679B (en) 1989-10-25
FI96116C (fi) 1996-05-10
JP2716191B2 (ja) 1998-02-18
IE62993B1 (en) 1995-03-08
HU209401B (en) 1994-05-30
US5079229A (en) 1992-01-07
PT89916B (pt) 1994-05-31

Similar Documents

Publication Publication Date Title
CA1223198A (en) Repair of tissue in animals
US5132408A (en) Fibroblast growth factor antagonists
Behrens et al. Biochemistry of the protein hormones
KR890003802A (ko) 재조합 dna 기술에 의해 제조된 소의 췌장 트립신 억제제, 그 제조 방법, 발현 벡터 및 재조합 숙주 및 그의 제약적 용도
RU95113418A (ru) Полипептиды, способы получения, днк, вектор, клетка, применение полипептида, фармацевтические композиции
KR940703860A (ko) 신규한 사람 쿠니즈형 프로테아제 저해제 및 그의 변이체(a novel human kunitz-type protease inhibitor and variants thereof)
KR940703854A (ko) 사람 쿠니즈형 프로테아제 저해제 변이체(a human kunitz-type protease inhibitor variant)
CA2370289A1 (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
ES2063350T3 (es) Nuevas proteinas con efecto inhibidor del tnf y su produccion.
KR880009045A (ko) 혈액 응고 방지성 펩티드
RU94036773A (ru) Домен i ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена i
KR880009125A (ko) 재조합 숙주에 의해 제조되는 췌장분비 트립신 억제제 및 그의 변이체, 그의 방법, 표현벡터 및 재조합 숙주 및 그의 제약상 용도
CA2000821A1 (en) Inhibitors of platelet binding
DE3066654D1 (en) Acyl peptides and pharmaceutical preparations thereof, as well as their manufacture and use
NO932148L (no) Fusjonspolypeptider
ATE84547T1 (de) Gereinigtes interleukin-1.
Joubert et al. The complete amino acid sequence of trypsin inhibitor DE-3 from Erythrina latissima seeds.
WO2002048180A3 (de) Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels
KR890014735A (ko) 변형 단백질
US5252718A (en) Fibroblast growth factor antagonists
Yamazaki et al. Purification and characterization of a cytolytic protein from purple fluid of the sea hare, Dolabella auricularia
Plevrakis et al. Proocytocin neurophysin convertase from bovine neurohypophysis and corpus luteum secretory granules: complete purification, structure-function relationships, and competitive inhibitor
KR920701244A (ko) 심실 펩티드 유도체
WO1998051322A1 (en) CONOPEPTIDES AuIA, AuIB AND AuIC
US5358707A (en) Oxidized variants of GM-CSF

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20011229

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee